Association of Metformin and Abdominal Aortic Aneurysm Repair Outcomes
Association of Metformin and Abdominal Aortic Aneurysm Repair Outcomes
复制标题
DOI：
10.1016/j.avsg.2021.02.048
复制
发表时间：
2021-08-04
影响因子：
1.5
通讯作者：
Chabowski, Mariusz
中科院分区：
文献类型：
--
作者：
Turowicz, Agnieszka;Kobecki, Jakub;Chabowski, Mariusz
背景：二甲双胍是治疗糖尿病的常用药物。最近有人提出，二甲双胍用于糖尿病患者可能会降低AAA（腹主动脉瘤）的患病率和减缓其进展以及破裂相关死亡率的风险。本研究的目的是研究二甲双胍治疗对AAA修复相关死亡率和手术并发症风险的影响。研究方法：在这项回顾性研究中，分析了306例接受腹主动脉瘤修复术的患者的临床资料，其中包括77例糖尿病患者。已对治疗结果进行了研究。从病史中获得糖尿病和二甲双胍处方状态。患者被分为三组：无糖尿病患者、接受二甲双胍治疗的糖尿病患者和接受其他降糖药物治疗的糖尿病患者。采用卡方独立性检验和比值比分析评估二甲双胍治疗与AAA直径、手术并发症和死亡率之间的相关性。为了评估影响AAA修复相关并发症和死亡率的因素，进行了多变量分析。结果如下：二甲双胍治疗对糖尿病患者AAA修复相关死亡率（P = 0.019）和并发症（P = 0.032）具有显著的保护作用。考虑到所有患者组（无糖尿病个体、接受二甲双胍治疗的糖尿病患者和接受其他降糖药物治疗的糖尿病患者），这些结果在统计学上不显著。结论：美托洛尔可降低糖尿病患者AAA修复相关死亡率和手术并发症的风险。
Background: Metformin is a commonly used drug in diabetes mellitus treatment. Recently it has been suggested that the use of metformin on diabetes mellitus patients may lower the prevalence and slow the progression of AAA (abdominal aortic aneurysm) as well as the risk of rupture related mortality. The aim of this studywas to investigate the impact of metformin treatment on the risk of AAA repair related mortality and surgical complications. Methods: In this retrospective study, the clinical data of 306 patients, including 77 patients with diabetes mellitus, who underwent abdominal aortic aneurysm repair has been analyzed. Treatment outcomes have been investigated. The diabetes and metformin prescription status has been obtained from the medical history. Patients were divided into three groups: diabetes free individuals, diabetics treated with metformin and diabetics treated with other glucose lowering drugs. The association between metformin treatment and AAA diameter, surgical complications and mortality were assessed using chi-square independence test and odds ratio analysis. In order to assess which factors are influencing AAA repair related complications and mortality a multi-variables analysis has been performed. Results: A significant protective effect of metformin treatment towards AAA repair related mortality ( P = 0.019) and complications ( P = 0.032) among patients suffering from diabetes mellitus was revealed. These findings were statistically insignificant when considering all groups of patients (diabetes-free individuals, diabetics treated with metformin and diabetics treated with other glucose lowering drugs). Conclusion: Metformin may lower the risk of AAA repair related mortality and surgical complications among patients with diabetes.